GenScript is best known for its gene synthesis capabilities, which we estimate is more than half of the life science services and products segment. In 2014, GenScript was the leader in gene synthesis, ...
R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech ...
In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...
GenScript Expands Range of Reagent Services, Adding Circular RNA and Lipid Nanoparticles Formulation
Building on GenScript's fast and dependable in-vitro transcription mRNA synthesis service, GenScript now offers the most comprehensive range of RNA formats critical, enabling fast delivery of complex ...
NANJING, China and SEOUL, South Korea, Nov. 18, 2019 /PRNewswire/ -- GenScript Biologics, a world leading bio-pharmaceutical CDMO company, announced today that it entered into an agreement with ABL ...
Panel discussions brought to life important insights into how AI could change the face of biopharma drug discovery in 2026 and beyond PISCATAWAY, N.J., Jan. 29, 2026 /PRNewswire/ -- GenScript Biotech ...
Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...
PISCATAWAY, N.J., March 12, 2024 /PRNewswire/ -- On March 11, 2024, GenScript Biotech Corporation (HK.1548), a world's leading technology and service provider of life science R&D and manufacturing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results